Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Axsome Thera
(NQ:
AXSM
)
76.02
+0.02 (+0.03%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
572,592
Open
75.34
Bid (Size)
70.65 (10)
Ask (Size)
76.50 (1)
Prev. Close
76.00
Today's Range
75.34 - 76.89
52wk Range
55.02 - 98.40
Shares Outstanding
47,190,970
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why Axsome Therapeutics Stock Is Sinking Today
June 11, 2024
A short-seller report is causing a sell-off of the biotech stock.
Via
The Motley Fool
15 Analysts Assess Axsome Therapeutics: What You Need To Know
June 05, 2024
Via
Benzinga
Performance
YTD
-1.35%
-1.35%
1 Month
-2.01%
-2.01%
3 Month
-1.11%
-1.11%
6 Month
+2.94%
+2.94%
1 Year
-11.71%
-11.71%
More News
Read More
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
June 05, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
June 04, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights
April 29, 2024
Via
Benzinga
Analyst Ratings For Axsome Therapeutics
April 10, 2024
Via
Benzinga
Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
June 03, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Participate in Upcoming Investor Conferences
May 30, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
May 29, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
May 28, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Hello Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
May 28, 2024
Via
Benzinga
3 Monster Stocks in the Making You Can Buy Right Now
May 18, 2024
Via
The Motley Fool
The 3 Most Undervalued Biotech Stocks to Buy in May 2024
May 11, 2024
Via
InvestorPlace
Prediction: These 2 Growth Stocks Could Triple By 2030
May 11, 2024
Via
The Motley Fool
Axsome Therapeutics to Present at Upcoming Investor Conferences
May 08, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript
May 06, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
AXSM Stock Earnings: Axsome Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 06, 2024
Via
InvestorPlace
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 06, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
May 01, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 30, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition
April 30, 2024
Via
InvestorPlace
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Billionaires Are Buying These 2 Ultra-High Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio?
April 16, 2024
Via
The Motley Fool
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
April 15, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 12, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.